<SEC-DOCUMENT>0001140361-22-035088.txt : 20220929
<SEC-HEADER>0001140361-22-035088.hdr.sgml : 20220929
<ACCEPTANCE-DATETIME>20220929080016
ACCESSION NUMBER:		0001140361-22-035088
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220929
FILED AS OF DATE:		20220929
DATE AS OF CHANGE:		20220929

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InflaRx N.V.
		CENTRAL INDEX KEY:			0001708688
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38283
		FILM NUMBER:		221277731

	BUSINESS ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745
		BUSINESS PHONE:		49 3641 508180

	MAIL ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Fireman B.V.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>brhc10042375_6k.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, LLC
         Document created using Broadridge PROfile 22.9.1.5075
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 18pt; font-weight: bold;">
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 30%; color: #000000;"></div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 18pt; font-weight: bold;"> FORM 6-K</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">
        <hr noshade="noshade" align="center" style="background-color: #54301A; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 30%; color: #54301A;"> </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">PURSUANT TO RULE 13A-16 OR 15D-16 UNDER</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">For the month of September 2022</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Commission File Number: 001-38283</div>
      <div><font style="color: #000000;"> </font><br>
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 30%; color: #000000; text-align: center;"></div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;">InflaRx N.V.
        <hr noshade="noshade" align="center" style="background-color: #54301A; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 0%; color: #54301A;"></div>
      <div style="text-align: center; color: #000000;">(Translation of registrant's name into English)</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 30%; color: #000000;">Winzerlaer


        Str. 2</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">07745 Jena, Germany</div>
      <div style="text-align: center; color: #000000;">(Address of principal executive office)</div>
      <div style="color: #000000;"><font style="color: #000000;"></font><br>
        <hr noshade="noshade" align="center" style="height: 2px; width: 30%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
        <div><br>
        </div>
        Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <div style="color: #000000;">Form 20-F &#9746; Form 40-F &#9744;</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <div style="color: #000000;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <div style="color: #000000;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
      <div style="color: #000000;"> <br>
      </div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: center; color: #000000; font-weight: bold;">INFLARX N.V.</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <div style="color: #000000;">
        <div style="color: #000000;">On September 29, 2022, InflaRx N.V. issued a press release titled &#8220;InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients.&#8221; A copy of the
          press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</div>
      </div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">SIGNATURES</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <div style="color: #000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zcb3bd973821549bab3f902f37de9197d">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">INFLARX N.V.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="3" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Date: September 29, 2022</div>
            </td>
            <td style="width: 5%; vertical-align: bottom;">
              <div>By:</div>
            </td>
            <td style="width: 40%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Niels Riedemann</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Name:</div>
            </td>
            <td style="width: 40%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Niels Riedemann</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Title:</div>
            </td>
            <td style="width: 40%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Chief Executive Officer</div>
            </td>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">EXHIBIT INDEX</div>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="za9f028ea29014d6fb6cf66bc5b33ddb4">

          <tr>
            <td style="width: 10%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Exhibit No.</div>
            </td>
            <td style="width: 1%; vertical-align: bottom;">&#160;</td>
            <td style="width: 89%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);"><a href="brhc10042375_ex99-1.htm">99.1</a></div>
            </td>
            <td style="width: 1%; vertical-align: top;">&#160;</td>
            <td style="width: 89%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0);">Press Release, dated September 29, 2022</div>
            </td>
          </tr>

      </table>
      <div><font style="color: #000000;"> </font><br>
      </div>
      <div style="text-align: center;"><br>
        <font class="BRPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10042375_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, LLC
         Document created using Broadridge PROfile 22.9.1.5075
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <div style="text-align: right;">
        <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
      </div>
      <div><br>
      </div>
      <img width="158" height="50" src="image2.jpg"></div>
    <div><br>
    </div>
    <div style="text-align: center;">InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z393b4ae64c6f4c76a4baa4031bc55727" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 17.85pt; vertical-align: top; text-align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Company also earns FDA Fast Track designation for vilobelimab to treat critically ill COVID-19 patients</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z3a53c51fa73340cc8065371bab41f331" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 17.85pt; vertical-align: top; text-align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>EUA submission based on Phase III results in critically ill COVID-19 patients, recently published in <font style="font-style: italic;">The Lancet Respiratory Medicine</font></div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z7e6d49c3f30a4a7b9edb0bd5cb5d37f7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 17.85pt; vertical-align: top; text-align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Request for EUA follows encouraging interactions with FDA in Type B meeting</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z7029b23cc4e34fd79dae15537ed960b0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 17.85pt; vertical-align: top; text-align: right;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>&#8220;Gohibic&#8221; conditionally accepted by FDA as proprietary name for vilobelimab</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-weight: bold;">Jena, Germany, September 29, 2022 </font>&#8211; InflaRx N.V. (Nasdaq: IFRX), a
      clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today submitted a request for Emergency Use Authorization (EUA) following encouraging interactions with the US Food and Drug
      Administration (FDA) at a Type B meeting held this summer. Additionally, InflaRx has been granted Fast Track designation from the FDA for vilobelimab for the treatment of critically ill, intubated, mechanically ventilated COVID-19 patients.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The EUA submission and Fast Track designation are based on the results of the PANAMO trial, one of the largest, global, 1:1 randomized, placebo-controlled Phase III
      studies conducted in invasively mechanically ventilated, critically ill COVID-19 patients. The detailed results of the study were recently published in the peer-reviewed journal, <u>The
          Lancet Respiratory Medicine</u>.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Prof. Niels C. Riedemann, CEO and Founder of InflaRx, said: &#8220;The EUA submission is an exciting milestone for InflaRx in the development of our lead candidate,
      vilobelimab. We believe that the data from our Phase III study strongly support the potential of vilobelimab to reduce the number of deaths in critically ill, invasively mechanically ventilated COVID-19 patients. Patients are still progressing to
      this critical status despite the availability of vaccines and other treatments for earlier disease stages and continue to show high mortality rates.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify;">He continued: &#8220;The FDA&#8217;s granting of Fast Track designation for vilobelimab in this indication underscores the need for effective new therapies to treat COVID-19
      patients who have progressed to critical disease with viral sepsis and organ failure. We look forward to working with the FDA on the review of our application with the goal of making vilobelimab available to patients in need.&#8221;</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;"> <img width="158" height="50" src="image2.jpg"></div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify;">The FDA&#8217;s Fast Track designation is designed to facilitate the development and expedite the review of treatments for serious medical conditions, thereby addressing unmet
      medical needs. Therapies that are included in this program may be eligible for more frequent interactions with the FDA to discuss the development path, and, if the program criteria are met, eligibility for a potential Rolling Review, Accelerated
      Approval, and Priority Review.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">About Vilobelimab</div>
    <div style="text-align: justify; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify;">Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates
      high selectivity towards its target in human blood. Thus, vilobelimab leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. Vilobelimab
      has been demonstrated in pre-clinical studies to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key &#8220;amplifier&#8221; of this response. Vilobelimab is believed to be the first monoclonal anti-C5a antibody
      introduced into clinical development. Vilobelimab has been shown to be well tolerated within clinical trials in different disease settings. Vilobelimab is currently being developed for various indications, including pyoderma gangrenosum and critical
      COVID-19. Vilobelimab is also in Phase II development for patients suffering from cutaneous squamous cell carcinoma.</div>
    <div style="text-align: justify;"><a name="z_Hlk114675939"></a><br>
    </div>
    <div style="text-align: justify;">The COVID-19 related work described herein is partly funded by the German Federal Government through grant number 16LW0113 (VILO-COVID). All responsibility for the
      content of this work lies with InflaRx.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">About InflaRx N.V.</div>
    <div style="text-align: justify; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify;">InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary technology to discover and develop first-in-class or
      best-in-class, potent and specific inhibitors of C5a and C5aR. Complement C5a and C5aR are powerful inflammatory mediators involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and
      the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit <u>www.inflarx.com</u>.</div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; font-weight: bold;"> <img width="158" height="50" src="image2.jpg"></div>
    <div style="text-align: justify; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; font-weight: bold;">Contacts:</div>
    <div style="text-align: justify; font-weight: bold;">InflaRx N.V.</div>
    <div style="text-align: justify;">Email: <u>IR@inflarx.de</u></div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">MC Services AG</div>
    <div style="text-align: justify;">Katja Arnold, Laurie Doyle, Andreas Jungfer</div>
    <div style="text-align: justify;">Email: <u>inflarx@mc-services.eu</u></div>
    <div style="text-align: justify;">Europe: +49 89-210 2280</div>
    <div style="text-align: justify;">US: +1-339-832-0752</div>
    <div><br>
    </div>
    <div style="text-align: justify;">FORWARD-LOOKING STATEMENTS</div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify;">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated
      by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; and similar expressions. Forward-looking statements appear in a number of
      places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned pre-clinical development and clinical trials,
      including the development of vilobelimab in several indications, including to treat pyoderma gangrenosum (PG) and critical COVID-19; our interactions with regulators regarding the results of clinical trials and potential regulatory approval pathways;
      our submission of an application to the FDA&#160; for emergency use authorization for vilobelimab to treat critical COVID-19 and the FDA&#8217;s review of the application; the impact of the COVID-19 pandemic on us; the timing and our ability to commence and
      conduct clinical trials; potential results from current or potential future collaborations; our ability to make regulatory filings, obtain positive guidance from regulators, and obtain and maintain regulatory approvals for our product candidates; our
      intellectual property position; our ability to develop commercial functions; expectations regarding clinical trial data; decisions regarding the strategic direction of our business; our results of operations, cash needs, financial condition,
      liquidity, prospects, future transactions, growth and strategies; the industry in which we operate; the trends that may affect the industry or us and the risks, uncertainties and other factors described under the heading &#8220;Risk Factors&#8221; in InflaRx&#8217;
      periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results,
      performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue
      reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.</div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="text-align: justify;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image2.jpg
<TEXT>
begin 644 image2.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '=!=P# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBBMCXX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU?\ X370?^?QO^_+_P"%'_":Z#_S^-_WY?\ PKRBB@#U?_A-=!_Y_&_[\O\
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M+\%W/^K\1V(S_P ]',?_ *$!6K;>)] O2!:ZYILY/017:,?T-?%M% 'W,""
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ&K:M;:-9-<W+>R(.KGT%
M$FHZE:Z7:-<W<H1!T'=CZ =S7F6N^*[W66:)28+3/$2GEA_M'O\ 3I6?JVKW
M6LWK7%RWLB _*@]!5"F(**** "BBB@ HHHH **** "BBB@ HHHH *VO"EM]J
M\362D<(_F'_@(R/U K%KLOAW;;]3N[DCB*((/JQ_^Q- 'HM%%%(8444A(4$D
MX &2: /)/%MQ]I\3WK \(PC'_ 0 ?US6)4UW.;F\GN#UED9S^)S4-,04444
M%%%% !1110!H:%;_ &K7K&'&0TRDCV!R?T%>SUY=X$M_.\2+)CB&)G_]E_\
M9J]1I#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N)^+6H?V?\,]88'#S
M(L"^^]@#_P".YKMJ\@_:#U#R?"VF6 .&N;LR'W"*?ZN* /G>BBBF,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .K\-?$;Q/X6*)8
MZB\EJO\ RZW/[R/'H >5_P" D5[CX/\ C1H/B'R[74R-*OSQB5OW+G_9?M]&
MQ]37S'10!]S @@$'(/0BEKY<\!_%K5O"1CLKS?J&D#CR6;YX1_L$]O\ 9/'T
MKZ2T/7-.\1:5%J6EW*SVT@X(ZJ>ZL.Q'I2$:-%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !65XCUR#P[H5SJ4^#Y2_(F?ON?NK^?Z9K5KQ+XOZ\;S
M6X=&B?\ <V:AY0#P9&']%Q^9J9RY5<]'*L%]<Q4:;VW?HOZL<!J6HW.K:C/?
MWDADN)WW.W]![#H*JT45RGZ?&*BE&.B04444#"BBB@ HHHH **** "BBB@ I
M0"2 !DGH!25TG@/2O[8\9Z= R[HHY//D]-J?-S]2 /QH2N[&5>K&C2E4ELDW
M]Q[[X;TL:+X;T_3L8:&%0_\ OGEOU)K5HHKL6A^35)RJ3<Y;O4****" HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %?._[0>H>=XITNP!RMM:&0^Q=B/Y(*^B*^3OBWJ']H?$S5V!RD+K
MOML4 _\ CV: .)HHHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *Z3P9XUU3P5JRW=C(7MW(%Q:L?DF7^A]#V^F17-T4
M?:?A[Q!I_B?18-4TV7S()1R#]Z-NZL.Q'^>*U*^3?AIXYF\%^(E:9W;2KDA+
MN(<X'9P/5?U&17U?%+'/#'-"ZR12*&1U.0P/((/I2$/HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@!DTJ00R32-MCC4LQ] .37RMJ=\^IZI=WTF=]Q,TISV
MR<XKZ.\:W/V3P5K$N<9M70'_ 'AM_K7S/6%5[(^SX5HKDJ5?-+]0HHHK(^N"
MBBB@ HHHH **** "BBB@ HHHH *]B^#.C>7:7VLR+\TK"WB)_NCEOS./^^:\
M@BC>:5(HU+2.P55'4D]!7T_X<TA-"\/6.FKC,$0#D=W/+'\R:TI*[N?.<2XK
MV6%5%;S?X+^D:E%%%=!\"%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D^(]6&C
MZ/+< CSF^2(?[1[_ (=?PK6KS#QSJ?VW6OLJ-F*U&WZN?O?T'X4 <P268LQ)
M).23WI***8@HHHH **** "BBB@ HI0"Q  )). !WKI])\#ZC?J)+H_8X3TWK
MES_P'M^- '+T5Z?:> ]'@'[_ ,ZY;OO?:/\ QW'\ZOIX4T./[NG1'_>)/\S0
M!Y#17K[>%=#;KIT7X$C^M5Y?!>A2=+1HSZI*W]30!Y117I%Q\/=.<?N+JXB;
M_:PP_D/YUCW7P]OXP3;74$X'9@4)_F/UH Y2U@:YNX;=?O2R*@_$XKW%5"(J
M*,*HP!7FOA_PWJ5KXEM#>V<D<4;%R_5<@''(XZXKTND,**** "N$^(UQQ86P
M/]^1A^0']:[NO+O'EQYWB1H\_P"IB5/S^;^M ',T444Q!1110 4444 %%%2V
ML)N;N&!>LLBH/Q.* /8=!M_LN@6,.,$0J2/<C)_4UHTBJ%4*HP , 4M(8444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 A(52Q(  R2:^)]9OCJFN:AJ!))N
MKF2;G_:8G^M?7GC/4/[+\$ZU>@X:.SEV'_:*D+^I%?&M !1113&%%%% !111
M0 4444 %%/$,I&1&Y!_V32^1+_SR?_ODT 1T5)Y$O_/)_P#ODT>1+_SR?_OD
MT 1T5)Y$O_/)_P#ODTP@@X((/H: $HHHH **** "BBB@ HHHH **** "BBB@
M KZ&^!/B_P#M#2)O#=W)FXL1YEL6/+0D\C_@)/Y,/2OGFMSP?KS^&?%FG:LI
M.R"8>:!_%&>''_?)- 'V7138Y$EC62-@R. RL#P0>AIU(04444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '+?$8$^ -6QUV)_Z&M?.5?3OBVT-]X1U:W499K60J/4@
M9'ZBOF*L*NY]SPM)/#3CVE^B_P @HHHK(^H"BBB@ HHHH **** "BBB@ HHH
M ). ,DT =U\*]!.J^*EO9$S;:>/-)/0R'[@_/)_X#7OE<QX"\.GPYX7@@E3;
M=S_OKCU#'HOX# ^N:Z>NF$;(_-,ZQOUO%RE'X5HOE_FPHHHJSR0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M &GQ/9+CA',A_P" @G^8%8M=?\/;??K%Q.1Q%#@?5B/Z T >D4444AA1110
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M#IUDF7<Y=R/EC7NQ]A_]:OI+0]&M- TB#3K),11#ECU=N['W-:4XW=SY[/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5E>)+G[)X<OI<X/E% ?=OE_K6K7*>/[CRM!CA!YFF (]@"?YX
MH \SHHHIB"BBB@ HHHH **** .[^'-M\U]=$= L:G\R?Z5WE<SX$M_)\-K)C
M_72L_P"7R_\ LM=-2&%%%% !1110 4444 %%%% !1110 4444 >=?$2XWZE:
M6^?]7$7_ !8__8UQM;OC"X^T>)[O!RL96,?@!G]<UA4Q!1110 4444 %%%%
M!UKV^QM_LNGVUO\ \\HE3\ABO'M&M_M6M64&,AYES],\_I7M-(84444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX=0XXR.F:@HH ZW_ (6%JW_/M9?]\/\ _%4?\+"U;_GVLO\ OA__ (JN2HH
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M9OV>=/\ ,US6=1(_U%LD /\ OMG_ -IU] UY1\ =/^S^"KN]88:ZO&P?554
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M^*H ^B**^=_^&A->_P"@/IO_ )$_^*H_X:$U[_H#Z;_Y$_\ BJ /HBBOG?\
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MCB*$X^I('\LUR5>A?#JWVV-[<X^_(J#_ (",_P#LU ':T444AA1110 4444
M%%%<-XN\6>7YFF:=)\_W9IE/3_9'OZF@!?%'C$PM)8:6_P X^62X!^[[+[^]
M<"26)))))R2>])13$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)/AN/#%BNLZK"/[8N4^5&'_'LA_A_P!X]_3IZY]0HHI""BBB@ HHHH ****
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MQM--M$M;&VAMK=!A8H4"J/P%6** "BBB@ HHHH **** "BBB@ HHHH ****
M"N0^)GA?_A*_!-Y:1)NO(!]HM<#DNH/R_B,C\177T4 ?#%%=W\6_"_\ PC7C
M>X,,>VRO\W,&!P,GYU_!L\>A%<)3&%%%% !1110 4444 %%%% !1110 5ZI\
M(OAL?$=XNN:M#_Q*;=_W4;#BY<=O]P=_4\>M8'PW\ W'C?6\2!XM*MB&NIAW
M]$7_ &C^@Y],_5=G9V^GV<-G:0I#;PH$CC08"J.@% $X  P!@"BBBD(****
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M0PHHHH \Z^(5[YFHVUDIXA0NWU;_ .L/UKC:T-;O?[0UN\NLY5Y#M_W1P/T
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MALCM)(TC'+,23]37KWBBX^S>&K]\X+1[!_P([?ZUX_3 ****!!1110 4444
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MM<_8](O+C.#'"S#ZXX_6KE<WXYN?(\-21@X,\BQ_KN_]EH \LHHHIB"BBB@
MHHHH **** -KPG:?:_$MFI&5C;S3_P !&1^N*]=KSKX=V^_5+NXQQ'"$_%C_
M /8FO1:0PHHHH **** "BBB@ HHHH *\L\;ZA]L\0/"IS';*(Q]>I_7C\*]*
MO[Q+"PGNY/NQ(6QZ^@_&O%)97GFDFD.7D8LQ]2>30 RBBBF(**** "BBB@ H
MHHH ]/\  5OY7ATRD<S3,V?88']#745E^'+?[-X=L(L8/DAB/=OF_K6I2&%%
M%% !1110!\\_M":AYOB72=/!R+>T:4CT+MC^2"O'J[CXO:A_:'Q,U8@Y2 I
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MZO&P?5550/UW5\W5]=?#'3_[-^&VAPXP7M_//_;0E_\ V:@#K:***0@HHHH
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MHI#"BBB@ KSWXBW&Z^LK;/W(VD/_  (X_P#9:]"KR?QG<?:/$]R <K$%C'X
M9_4F@# HHHIB"BBB@ HHHH ***L6-O\ :[^WMQ_RUE5/S.* /8-%M_LFB64&
M,%85W?7&3^M7Z.@P**0PHHHH **** "BBB@ HHHH **** "BBJVHW'V33+JX
MSCRHF<?4"@#QW5KC[7J]Y<9R))F8?3/'Z53HHIB"BBB@ HHHH **** -_P &
M6_VCQ/;$C*Q!I#^ ./U(KUBO//AU;[K^]N<?ZN((/^!'/_LM>ATAA1110 5Y
M7XXD+^*)E/\  B*/RS_6O5*\E\8MN\5WQ]"@_P#'%H PJ***8@HHHH ****
M"BBB@#UGP8,>%+/WWG_Q]JWJQ/"( \*V./[K?^A&MND,**** "BBB@ HHHH
M*Y;QQJXL=)^QQM^_NOE..R=_SZ?G732RQP0O-*P2-%+,QZ "O'-<U1]8U::[
M;(0G;&I_A0=!_7\: ,ZBBBF(**** "BBB@ HHHH *ZKP!;^;K[RD<0PL0?<D
M#^1-<K7?_#FWQ!?7)'WF6,'Z D_S% '<4444AA1110 5YW\;-0^Q?#6[B!PU
MW/% /^^MY_1#7HE>)?M#ZAML=#TT'_62R3L/3: H_P#0FH \%HHHIC"BBB@
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M444 %%%% 'H?P[M-EA=W9',L@C'T49_K^E=I63X9M/L7ARRB(PQC\QOJW/\
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M !1110 4444 %8'C.X^S^&+H X:4K&/Q(S^@-;]<7\1;C;865MG_ %DI<_\
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M%(LB,5=2&4CJ"*]5\->)H-9MDBF=4OE&'CZ;_=?\.U(9T%%%% !12$A5+,0
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M;FYE>6>5R\DCG)9CR2345,84444 %%%% !1110 Z.-Y9%CC1GD<A551DDGH
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M< 2< 9)KU?PGH0T?3=\R_P"ES@-)_LCLO^/O0!A_$"2.WL].T^%0L:Y8*.@
M  _F:X2NJ\?S>9X@2,'B*!1^))/]17*T %%%% !1110 4444 ;?A&+SO%%BI
MZ*S/^2D_TKURO+_ <>_Q(&_YYPNW\A_6O4*0PHHHH **** /*_CWJ'V;P+;V
MBGYKN\12/55#,?U"U\V5[5^T/?[]4T33@?\ 50R3L/\ >8*/_0#7BM,84444
M %%%% !1110 5=T>Q.IZW8:>N<W5S'",?[3 ?UJE7;?"73_[0^)FCJ1E(7:=
MO;8I(_\ 'L4 ?6  50J@  8 %+112$%%%% !1110 4444 %%%% $-W:PWUE/
M:7,8D@GC:.1#T96&"/RKXU\4:%/X9\2W^CSY+6TI56(^^AY5OQ4@U]H5XE\?
MO"_FVMGXFMX_FAQ;76!_"3E&/T.1_P "% '@M%%%,84444 %%%% !1110!V'
MPS\4_P#"*>-;2[E?;9SG[/=<\!&(^;_@)P?P-?6]?#%?57PB\4_\)+X)@CFD
MW7NGXMI\GD@#Y&_%>/J#2$=[115'6-7LM"TFXU/49A#:VZ;G8_H!ZDG@"@#-
M\8^+;#P;H$NI7AW/]R" '#3/V ]O4]A7R3KNN7_B/6;C5-1E,EQ.V3Z*.R@=
M@!P*U/''C*]\:Z^]_<YCMTREK;YXB3_$]2?Z 5S5,84444 %%%% !1110 5V
MOPT\"R^-?$(69672[4A[N0<9'9 ?5OT&37-:)HU[X@UFVTO3XO,N;A]JCL!W
M8^@ Y/TKZ\\)^&++PCX>M])LAD(-TLI&#+(?O,?\\  4 :\$,5M!'!!&L<,:
MA$11@*H&  /2I***0@HHHH ^??C]X<^S:O8^(84Q'=K]GG('_+11\I/U7C_@
M%>-5]A>/_#H\4>"M1TU4W7!C\VW_ .NJ\K^?3Z$U\>D$'!&".HIC"BBB@ HH
MHH **** "O5_@7XI_LOQ-+H=Q)BVU(?N\GA9E''YC(^H6O**EMKF:SNH;JWD
M,<T+B2-UZJP.0?SH ^XJ*Q?"7B&'Q3X7L-7BP#/'^\0?P2#AE_ @_ABMJD(*
M*** "BBB@ HHHH **** ,KQ+<?9?#=_)G!,10?\  OE_K7CM>F^/[CRM 2$'
MF:901[ $_P P*\RIB"BBB@ HHHH **** "N_^'-OB"^N2/O,L8/T!)_F*X"O
M5/!%OY'AF%L8,SM(?SQ_(4 ='1112&%%%% !1110!P?Q&N/FL+8'H&D8?D!_
M6N$KI?'5QYWB5X\\0Q*G_LW_ +-7-4Q!1110 4444 %%%% !7M&B6_V30[&#
M&"L*[OJ1D_K7C]C;F[O[>W'_ "UE5/S.*]O P,"D,**** "BBB@ HHHH ***
M* "N2^(-QY>B00 \RS#/T /]<5UM>>_$6XW7UE;9^Y&SD?[QQ_[+0!Q5%%%,
M04444 %%%% !1110!ZKX(M_(\,0MC!F=I#^>/Y 5T54])M_LFCV<&,&.%0?K
MCG]:N4AA1110 5'/*L%O),WW8T+'Z 9J2LCQ3<?9O#-\^<%H_+'_  ([?ZT
M>0N[22,['+,22?>FT44Q!1110 4444 %%%% '4> K?SO$7FD<0PLV?<X7^IK
MT^N&^'-OB*^N2.K+&#],D_S%=S2&%%%% !1110 4444 %%%% !1110 4444
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M#R_P;;_:/$]KD96,-(?P!Q^I%>LU#%:6T#[XK>*-L8RB &IJ0!1110 4444
M%8GBZX^S^&+P@\NHC'XD _IFMNF2Q1S)LEC21>N'4$4 >%T5[=_9UC_SYV__
M 'Z7_"C^SK'_ )\[?_OTO^%,#Q&BO;O[.L?^?.W_ ._2_P"%']G6/_/G;_\
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M_P#WZ7_"C^SK'_GSM_\ OTO^%,#Q&BO;O[.L?^?.W_[]+_A1_9UC_P ^=O\
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M ^G_ /@,G^% 'Q517VK_ ,(]HG_0'T__ ,!D_P */^$>T3_H#Z?_ . R?X4
M?%5%?:O_  CVB?\ 0'T__P !D_PH_P"$>T3_ * ^G_\ @,G^% 'R-X,T_P#M
M3QKHMD1E9+R+>/\ 9# M^@-?9=48-%TJVF6:WTRSBE7[KQP*K#Z$"KU(0444
M4 %%%% !1110 4444 %%%% !1110 5RGQ'\,#Q7X*O;&--UW&//M?7S%Z#\1
ME?QKJZ* /A@@@X(P117??%_PO_PCGCB>6&/;9:CFYAP. Q/SK^#<_1A7 TQA
M1110 4444 %%%% !114D,KV\\<T> \;!UR,C(.1Q0!'17U[X57P]XG\,V&L0
M:/IP^T1@N@MD^1QPR].Q!K8_X1[1/^@/I_\ X#)_A0!\545]J_\ "/:)_P!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#@/B_X7_P"$C\$3RPQ[KW3LW,.!R5 ^=?Q7GZJ*^5Z^
MYB 001D'J*^1/B-X8/A/QI>V")MM)#Y]KZ>6W0?@<K^% '*4444QA1110 44
M44 %%%% 'M'P#\4_9M1NO#5Q)^[N0;BUR>D@'S*/JHS_ ,!/K7O]?$>EZE<Z
M/JMKJ5H^VXM95EC/N#G!]J^S-#U>WU_0[+5;0YANHA(HS]W/53[@Y!^E(1H4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
